TransMedics (TMDX): Can the Stock Close the Gap to the $100 Analyst Target With a +31% Move?
Key Takeaways
- The central price target of $100 is the arithmetic mean of roughly ten current, attributable analyst price targets, rounded to a clean level.
- The latest verified price is about $76.52, implying a required move of roughly 31% — a substantial but not extreme gain.
- Current analyst targets span a wide range from $65 (Stifel) to $120 (Barclays and TD Cowen), reflecting genuine disagreement about the stock's growth trajectory.
- Supporting factors include double-digit transplant procedure growth and strong expected revenue expansion; the main risks are slowing profit growth, valuation, and competitive and reimbursement uncertainty.
- The target is a research estimate, not a guarantee, and reflects a roughly 12-month horizon rather than a near-term forecast.
Analyst Price Targets and the Consensus Picture
TransMedics Group, Inc. (TMDX) develops the Organ Care System that preserves donor organs during transport for transplants. Analyst coverage remains broad yet divided. Compiling the latest attributable targets from Barclays ($120, Overweight), TD Cowen ($120, Buy), Needham ($106, Buy), Piper Sandler ($100, Overweight), Canaccord Genuity ($95, Buy), J.P. Morgan ($92, Hold), Evercore ISI ($90, Buy), UBS ($77, Hold), and Stifel ($65, Hold) yields a range of $65 to $120 with a mean near $97, which rounds neatly to the $100 central target. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Ratings show real dispersion: six to eight analysts lean Buy or Overweight, four to six sit at Hold or Neutral, and at least one source remains bearish. Optimistic voices highlight rising U.S. transplant volumes and revenue momentum, while skeptics focus on fading profitability and increasing competition. Several firms have already lowered targets this year, including Piper Sandler to $100 from $120 in August, Needham to $106 from $142, and Evercore ISI to $90 from $100.
Where the Stock Stands Today and the Road to $100
After closing recently at $76.52, the shares sit well below the 52-week high of $156.00 and modestly above the 52-week low of $60.11. Closing the gap to $100 would require a gain of about 31%. Year to date the stock has dropped roughly 37%, which has compressed valuation metrics: the trailing P/E stands near 20 while the forward P/E is around 42. Consensus estimates project revenue rising about 22% in 2026 to roughly $742 million and another 18% in 2027 to near $875 million, with EPS expected to fall to about $1.51 in 2026 before recovering toward $2.25 in 2027. A move toward $100 will likely require renewed confidence that earnings growth is reaccelerating alongside revenue.
Factors That Could Help the Stock Approach the Target
The bullish thesis centers on steady demand for transplants. Data on U.S. procedures continue to show mid-teens or stronger year-over-year growth, and TransMedics leads in the still-emerging machine perfusion segment that improves on traditional cold storage. Recurring revenue from logistics, broader program adoption, and greater use of the OCS across heart, lung, and liver cases all reinforce the growth story. Stronger quarterly results or raised guidance could lift both analyst targets and the share price.
Obstacles That Could Keep the Target Out of Reach
Profitability trends and valuation remain the primary concerns. Net income declined year over year in the most recent quarter despite revenue growth, and consensus forecasts a notable EPS drop for full-year 2026. Competitive intensity, staffing limits at hospitals, reimbursement questions, and the expense of building a national logistics network could further pressure margins. At a forward P/E near 42, the valuation already embeds significant growth expectations, so any shortfall in guidance, transplant volumes, or margins could push $100 further away. The broad spread between $65 and $120 itself underscores how divided analysts remain.
Technical Levels Worth Watching
The 52-week range of $60.11 to $156.00 frames the current structure, with the price in the lower half. The $60 zone from the May 2026 low serves as key support, while $80 represents near-term resistance. Beyond that, $100 functions as both the central target and a psychological barrier; the $120 area, where several targets cluster, marks the next significant resistance and aligns with the high end of current forecasts.
Time Horizon and Key Items to Follow
Most analyst targets reflect a roughly 12-month research horizon. The next earnings release, expected in late October 2026, stands out as the nearest catalyst; investors will focus on revenue, EPS, margin trends, and any updates to guidance. Transplant-volume reports, competitive developments, target revisions, and reimbursement news will also influence whether the shares can move closer to $100.
Adding AI Daily Buy/Sell Signals to the Process
In my own analysis I often reference Tickeron's AI Daily Buy/Sell Signals for a systematic overlay. The platform applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals that reflect evolving market conditions, technical patterns, and data-driven insights. For a name like TMDX that has shown notable volatility, these automated signals can help track momentum shifts alongside the fundamental picture.
Final Assessment
The $100 central target, drawn from the average of current analyst estimates, lies roughly 31% above the latest price and represents a meaningful yet plausible advance. The supporting case built on transplant-volume growth and recurring revenue remains plausible, yet near-term earnings pressure, a premium forward valuation, and the wide dispersion of targets from $65 to $120 create real hurdles. Whether TMDX can reach $100 will depend largely on whether upcoming results and guidance restore confidence in the earnings trajectory. As with any high-beta growth-stage medical technology stock, outcomes remain uncertain and no single target should be treated as a firm prediction.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
TMDX in upward trend: price may jump up because it broke its lower Bollinger Band on October 01, 2026
TMDX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 23 of 26 cases where TMDX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where TMDX advanced for three days, in 258 of 305 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TMDX as a result. In 69 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
TMDX moved below its 50-day moving average on September 28, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TMDX crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TMDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for TMDX entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 28 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.537) is normal, around the industry mean (10.930). P/E Ratio (21.433) is within average values for comparable stocks, (100.178). Projected Growth (PEG Ratio) (0.709) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (5.033) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 74 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TMDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. TMDX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of a proprietary system for preserving human organs for transplant
Industry MedicalNursingServices
Advertisement